Clene Inc
Clene Inc (CLNN) is a small‑cap, clinical‑stage biotechnology company (market cap roughly $86.8m) developing novel therapies aimed at neurological and related disorders. Investors should know Clene spends heavily on research and development and may not yet generate sustainable revenue; its value is driven largely by clinical trial progress, regulatory milestones and partner/licensing developments. That profile can produce meaningful upside if trials succeed, but also significant downside if programmes fail or funding becomes constrained. Liquidity can be limited in smaller stocks, amplifying price swings. Before considering an investment, review the company’s latest filings, cash runway and trial data, and compare its science and management team with peers. This summary is educational, not personalised advice — therapeutic development is inherently risky, and past performance does not predict future returns. Consider whether a speculative biotech aligns with your risk tolerance and investment horizon.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Clene Inc's stock with a target price of $111.75, indicating strong potential growth.
Financial Health
Clene Inc has modest revenue and strong profit margins, but cash flow remains a concern.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CLNN
Hope & Optimism Portfolio
This collection brings together pioneering companies working to solve humanity's biggest challenges through groundbreaking innovation. These carefully selected stocks represent visionaries building transformative technologies in medicine, energy, and beyond.
Published: June 18, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Milestones Ahead
Trial readouts and regulatory milestones can meaningfully affect value, though outcomes are uncertain and may increase volatility.
R&D-Driven Value
The company’s prospects hinge on science and trial results; strong data can create opportunities, but development is costly and risky.
Liquidity & Funding
As a small‑cap, cash runway and access to capital matter; funding news can shift the share price materially—consider suitability for your portfolio.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
